We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

4 hedge funds and large institutions have $467K invested in Oasmia Pharmaceutical AB in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

82% less capital invested

Capital invested by funds: $2.55M → $467K (-$2.08M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$48.1K
2
Deutsche Bank
Deutsche Bank
Germany
+$2.1K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$2.02M
2
TRCT
Tower Research Capital (TRC)
New York
-$17

OASM Hedge Fund Activity: Q2 2016 in Review

4 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q2 2016, worth a combined $467K — down 82% from $2.55M a quarter earlier.

Fund positioning in OASM was balanced in Q2 2016: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $48.1K. The largest seller was Sabby Management, exiting entirely with an estimated $2.02M sold.

  • 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $467K of Oasmia Pharmaceutical AB stock for Q2 2016, down 82% quarter-over-quarter.
  • 2 funds opened new Oasmia Pharmaceutical AB positions in Q2 2016 and 2 closed out, a net change of 0 holders.
  • The largest Oasmia Pharmaceutical AB buyer in Q2 2016 was Citadel Advisors, an estimated $48.1K added.
  • The largest Oasmia Pharmaceutical AB seller in Q2 2016 was Sabby Management, an estimated $2.02M sold.

Based on aggregated 13F filings for Q2 2016.